GLP-1 agonists are becoming increasingly significant in the treatment of diseases like diabetes, metabolic syndrome, and obesity, mimicking the action of endogenous GLP-1, an anorectic hormone produced in multiple human body tissues including the intestine, pancreas, and central nervous system [20,21]. This evidence concerns the gene GCG and metabolic syndrome.